Key result
Maternal intake of metamizole during pregnancy was associated with premature closure of the fetal ductus arteriosus and right ventricular hypertrophy at 37 weeks gestation.
Why the study?
The prevalence of intra-uterine dysfunction of the ductus arteriosus is unknown and its clinical consequences are poorly understood.
Case Report (n=1)
Maternal intake of metamizole during pregnancy can lead to premature closure of the fetal ductus arteriosus, which can be managed successfully with prompt delivery.
Answers are grounded in this paper and cite their sources.
Alerts to possible metamizole risks in pregnancy; leaves open prevalence and consequences of fetal ductus closure.
The prevalence of intra-uterine dysfunction of ductus arteriosus is unknown and the clinical consequences are poorly understood. We report a case of prenatal diagnosis of premature closure of the ductus arteriosus due to maternal intake of metamizole during pregnancy. Fetal echocardiography at 37 weeks of gestation revealed a right ventricular hypertrophy and suspected stenosis of the tricuspid valve. A cesarean section led to an excellent neonatal outcome. The aim of this report is to show echocardiographic abnormalities and outcomes of this rare phenomenom.
No takes yet. Share an insight, caveat, or question.
Bermejo Rosa (2023) conducted a case report in Premature closure of the ductus arteriosus (n=1). Maternal intake of metamizole was evaluated on Echocardiographic abnormalities and neonatal outcome. Maternal intake of metamizole during pregnancy was associated with premature closure of the fetal ductus arteriosus and right ventricular hypertrophy at 37 weeks gestation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: